Keros Therapeutics Has Closed Screening For The TROPOS Trial, A Phase 2 Clinical Trial Of Cibotercept In Combination With Background Therapy In Patients With Pulmonary Arterial Hypertension

Author: Benzinga Newsdesk | September 03, 2024 08:24am

Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that the Company has closed screening for the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"). As a result, Keros expects to complete enrollment by the end of September and present topline data in the second quarter of 2025.

Posted In: KROS